Whats up with atazanavir, the new once-a-day protease inhibitor?
When will it be available? Answer: Currently there is a limited expanded access program for atazanavir (ATV) for people who have problems with cholesterol and triglyceride elevations from the other currently available protease inhibitors (PIs). This program has been slow in development and as a result has not been available too as many people with access to the drug as had been hoped for. The FDA scheduled a meeting of the Antiretroviral Advisory Committee to review the ATV application for FDA approval. From the FDA comes this notice: “On May 13, 2003, the committee will discuss new drug applications (NDA) 21-567 and 21-568, Reyataz (atazanavir sulfate) capsules and powder for oral use, Bristol-Myers Squibb Co., proposed for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.” ATV is a once-a-day PI, dosed at 400 mg a day. The main side effect of the drug is an elevation in bilirubin, due to an effect on enzymes in the liver. T
Related Questions
- Does protease inhibitor inhibit complement activation caused by the immune complex associated with islet cell surface antibody?
- Did cathelicidins, a family of multifunctional host-defense peptides, arise from a cysteine protease inhibitor?
- are etiologies changing since the introduction of protease inhibitor therapy?
